Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA-A2-restricted WT1-reactive CD8+ T cells

SHIN KAN[1,2], TSUUSE BITO[1,2], MASAMORI SHIMABUKU[3], JUNICHI TAGUCHI[3], TOSHIFUMI OHKUSA[1], SHIGETAKA SHIMODAIRA[4], HARUO SUGIYAMA[5] and SHIGEO KOIDO[1,2]

[1]Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital; [2]Institute of Clinical Medicine and Research, The Jikei University School of Medicine, Kashiwa, Chiba 277-8567; [3]Tokyo Midtown Center for Advanced Medical Science and Technology, Tokyo 107-6206; [4]Department of Regenerative Medicine, Kanazawa Medical University, Ishikawa 920-0293; [5]Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan

Abstract. The proliferation and activation of CD4+ T helper 1 (Th1) cells and CD8+ cytotoxic T lymphocytes (CTLs) that produce interferon-γ (IFN-γ) is an essential action of effective cancer vaccines. Recently, a novel Wilms' tumor 1 (WT1) helper peptide (WT1 HP$_{34-51}$; amino acid sequence, WAPVLDFAPPGASAYGSL) applicable for various human leukocyte antigen (HLA) subtypes (HLA-DR, HLA-DP and HLA-DQ) was reported to increase peptide immunogenicity; however, the function of WT1 HP$_{34-51}$ remains unclear. In the present study, mature dendritic cells (mDCs) pulsed with WT1 HP$_{34-51}$ (mDC/WT1 HP$_{34-51}$) activated not only WT1-specific CD4+ T cells but also CD8+ T cells that produced IFN-γ following stimulation with immature dendritic cells (imDCs) pulsed with WT1 killer peptide (imDC/WT1 KP$_{37-45}$) in an HLA-A*02:01- or HLA-A*02:06-restricted manner. Furthermore, the activated WT1-reactive CD4+ Th1 cells were predominantly effector memory (EM) T cells. In 5 of 12 (41.7%) patients with cancer carrying the HLA-A*02:01 or HLA-A*02:06 allele, WT1-reactive CD8+ T cells stimulated with mDC/WT1 HP$_{34-51}$ enhanced their levels of WT1 KP$_{37-45}$-specific IFN-γ production, with an increase >10%. Simultaneous activation of CD4+ and CD8+ T cells occurred more often when stimulation with mDC/WT1 HP$_{34-51}$ was combined with imDC/WT1 KP$_{37-45}$ restimulation. These results indicated that the novel mDC/WT1 HP$_{34-51}$ combination induced responses by WT1-specific EM CD4+ Th1 cells and HLA-A*02:01- or HLA-A*02:06-restricted CD8+ CTLs, suggesting its potential as a WT1-targeting cancer vaccine.

Introduction

Dendritic cells (DCs) are antigen-presenting cells that regulate the immune response via interactions between major histocompatibility complex (MHC) molecules on DCs and T-cell receptors on T cells alongside costimulatory molecules (1). Cancer vaccines using DCs loaded with antigenic peptides, tumor lysates, mRNA, DNA or whole tumor cells are an approved approach for enhancing a patient's own immune system to eradicate tumor cells (2). In clinical trials, MHC class I-restricted peptide-loaded DCs have been most commonly used to induce antigen-specific CD8+ cytotoxic T lymphocyte (CTL) responses and, in some cases, have been associated with clinical benefits; however, clinical efficacy has been limited (3,4). It has been reported that activation of CD4+ T helper type 1 (Th1) cell responses via MHC class II molecules on mature DCs (mDCs) is essential for supporting CD8+ CTL priming, memory formation, recruitment to tumor tissue and tumor cell recognition (5-7). Therefore, several long peptides targeting tumor-associated antigen (TAA)-specific CD4+ cells have been developed for the treatment of patients with cancer (5-10). Our previous study reported the clinical benefits of using MHC class I and II peptide-pulsed mDC vaccines to simultaneously induce TAA-specific CD4+ Th1 cells and CD8+ CTLs (4).

At present, numerous TAAs, such as Wilms' tumor 1 (WT1), HER-2/neu, gp100 and tyrosinase, have been isolated and incorporated into cancer vaccine preparations in the form of peptides (3-10). A promising target for cancer vaccines, WT1 was ranked as the top antigen among 75 TAAs due to its high immunogenicity (11). WT1 is highly expressed in various types of tumor and serves oncogenic roles in their formation (12-14). Additionally, WT1 has been successfully

Correspondence to: Dr Shin Kan or Dr Shigeo Koido, Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Kashiwa Hospital, 163-1 Kashiwa-shita, Kashiwa, Chiba 277-8567, Japan
E-mail: kan@jikei.ac.jp
E-mail: shigeo_koido@jikei.ac.jp

applied to induce both CD4[+] Th1 cells and CD8[+] CTLs (15,16). WT1-specific CD4[+] Th1 cells contribute to the induction and maintenance of WT1-specific CD8[+] CTLs by establishing the required cytokine milieu via cytokine secretion, including interleukin (IL)-2 and interferon-γ (IFN-γ) (15). In our previous study, mDCs were pulsed with three types of MHC class I- or class II-restricted WT1 peptide: i) 126-134 (amino acid sequence, RMFPNAPYL) for human leukocyte antigen (HLA)-A*02:01/02:06; ii) 235-243 (amino acid sequence, CYTWNQMNL) for HLA-A*24:02; and iii) 332-347 (amino acid sequence, KRYFKLSHLQMHSRKH) for MHC class II (4). Patients with advanced pancreatic ductal adeno-carcinoma (PDA) were then treated with pulsed mDCs in combination with standard chemotherapy. In the clinical trial, 4 of 7 patients with PDA exhibited strongly positive WT1-specific immunity, resulting in prolongation of overall survival. However, WT1-specific immunity was not induced in the remaining 3 patients. Therefore, a novel WT1 helper peptide with increased immunogenicity may be essential for the induction and maintenance of antitumor immunity in clinical trials to generate more successful results.

Recently, a novel WT1 helper peptide (WT1 HP$_{34-51}$; amino acid sequence, WAPVLDFAPPGASAYGSL) was identified (17). Of note, WT1 HP$_{34-51}$ contains a killer WT1 peptide (WT1 KP$_{37-45}$; amino acid sequence, VLDFAPPGA) that has affinity for HLA-A*02:01 (18). Accordingly, the novel peptide WT1 HP$_{34-51}$ may induce not only WT1-specific CD4[+] Th1 cells but also CD8[+] CTLs simultaneously, at least partially, in an HLA-A*02:01-restricted manner. Thus far, the function of WT1 HP$_{34-51}$ remains unclear. In the present study, the impact of mDCs pulsed with the novel peptide WT1 HP$_{34-51}$ (mDC/WT1 HP$_{34-51}$) on the induction of WT1-reactive antitumor immunity was assessed.

Materials and methods

Prediction of peptide-MHC class I binding or peptide-MHC class II molecules. WT1 peptide-MHC class I binding affinity was predicted by the NetMHC 4.0 server-prediction program (http://www.cbs.dtu.dk/services/NetMHC-4.0). Moreover, WT1 peptide-MHC class II binding affinity was predicted by the NetMHCII-2.3 server-prediction program (https://services.healthtech.dtu.dk/service.php?NetMHCII-2.3).

Patient characteristics. The present study was jointly reviewed and approved by the Ethics Committee of the Jikei Institutional Review Board, Jikei University School of Medicine and the Clinical Study Committee of Jikei University Kashiwa Hospital [approval no. 29-063 (8679)]. All patients provided written informed consent for the use of their samples in scientific research before samples were collected. To assess the stimulatory ability of mDC/WT1 HP$_{34-51}$ for the induction of CD8[+] CTLs restricted by HLA-A2, 14 patients (7 male, 7 female; aged 37-88 years) with various types of cancer (cancer of the oropharynx, lungs, esophagus, stomach, breast, pancreas, ovary, gallbladder, biliary duct, prostate or uterus) expressing an HLA-A2 allele [02:01 (n=5), 02:06 (n=7) or 02:07 (n=2)] were enrolled in the Tokyo Midtown Center for Advanced Medical Science and Technology between August 2017 and April 2019 (Table I).

Preparation of WT1-pulsed DCs. Peripheral blood mono-nuclear cells (PBMCs) were collected from the 14 patients, none of whom had received cancer vaccines, via leukapheresis and cryopreserved at the Tokyo Midtown Center for Advanced Medical Science and Technology. PBMCs were isolated using a Ficoll-Plaque Premium (Cytiva) density gradient solution, cryopreserved and stored for future experiments. After cryo-preserved PBMCs were thawed and washed, their viability was assessed using trypan blue solution (Sigma-Aldrich; Merck KGaA). Trypan blue staining was performed according to the manufacturer's protocols. Cell viability was assessed under a CK40-F100 light microscope (magnification, x100; Olympus Corporation). Subsequently, the cells were incubated in serum-free AIM-V medium (Gibco; Thermo Fisher Scientific, Inc.) in a 10-cm Primaria cell culture dish with surface-modi-fied polystyrene for enhanced cell culture (Corning Inc.) under 5% CO_2 at 37°C in a humidified incubator. After >30 min, plastic-adherent monocytes and nonadherent (NAD) cells were isolated by washing with gentle pipetting. NAD cells were cryopreserved in Bambanker solution (Nippon Genetics Co., Ltd.) and used for induction of WT1-reactive T cells. Adherent monocytes were cultured in serum-free AIM-V medium containing granulocyte macrophage colony-stimulating factor (GM-CSF; 50 ng/ml; Primmune Inc.) and IL-4 (50 ng/ml; R&D Systems, Inc.) under 5% CO_2 at 37°C in a humidified incubator for 5 days to generate immature DCs (imDCs). Autologous imDCs were cryopreserved until they were pulsed with WT1 peptides or cocultured with NAD cells.

The viability and function of mDCs were not altered by whether fresh or cryopreserved PBMCs or imDCs were used for mDC production (19). Therefore, cryopreserved imDCs were used to prepare WT1-pulsed DCs in the present study. To generate WT1 peptide-pulsed autologous mDCs, cryo-preserved imDCs (1x10[5]) were thawed and incubated under 5% CO_2 at 37°C in a humidified incubator for 24 h with 100 μg WT1 HP$_{34-51}$ or WT1 KP$_{37-45}$ (all peptides obtained from Greiner Bio-One GmbH) in the presence of GM-CSF (5 ng/ml), prostaglandin E2 (50 ng/ml; Daiichi Fine Chemical Co., Ltd.) and lyophilized preparations of a penicillin-killed, low-virulence strain of *Streptococcus pyogenes* (OK-432; 10 μg/ml; Chugai Pharmaceutical Co., Ltd.). Autologous imDCs (1x10[4]) were also cultured with 25 μg WT1 HP$_{34-51}$ or WT1 KP$_{37-45}$ under 5% CO_2 at 37°C in a humidified incubator for 24 h to generate WT1 peptide-pulsed imDCs, which were used as a second stimulator.

Phenotypes of DCs and NAD cells. To assess DC phenotypes, imDCs or mDCs (1x10[5]/100 μl) were washed, incubated with Clear Back human Fc receptor blocking reagent (dilution 1:20; cat. no. MTG-001; MBL Life Science) for 5 min at 4°C and then stained with the following monoclonal antibodies (mAbs) at 4°C for 30 min: Fluorescein isothiocyanate (FITC)-conjugated anti-human HLA-ABC (dilution 1:20; cat. no. 311404; clone W6/32), anti-CD80 (dilution 1:20; cat. no. 305206; clone 2D10), anti-CD40 (dilution 1:20; cat. no. 334306; clone 5C3; all from BioLegend, Inc.); FITC-conjugated anti-CD14 (dilution 1:20; cat. no. 11-0149-42; clone 61D3; eBioscience; Thermo Fisher Scientific, Inc.); and phycoerythrin (PE)-conjugated anti-human HLA-DR (dilution 1:20; cat. no. 307606; clone L243), anti-CD11c (dilution 1:20; cat. no. 301606; clone 3.9),

Table I. Patient characteristics.

Patient	Sex	Age, years	Cancer	HLA-A
1	Male	69	Lung and esophagus	02:01/26:01
2	Female	49	Breast	02:01/11:01
3	Female	82	Stomach	02:01/24:02
4	Male	45	Pancreas	02:01/24:02
5	Male	59	Gallbladder and bile duct	02:01/24:02
6	Male	52	Oropharynx	02:06/24:02
7	Male	88	Stomach	02:06/26:03
8	Female	47	Ovary	02:06/24:02
9	Female	47	Ovary	02:06/11:01
10	Female	70	Pancreas	02:06/24:02
11	Male	65	Prostate	02:06
12	Female	60	Ovary	02:06/24:02
13	Female	37	Uterus	02:07/24:02
14	Male	46	Pancreas	02:07/24:02

HLA, human leukocyte antigen.

anti-CD83 (dilution 1:20; cat. no. 305308; clone HB15e) and anti-CD86 (dilution 1:20; cat. no. 305406; clone IT2.2; all from BioLegend, Inc.). In addition, to assess NAD phenotypes, NAD cells ($1x10^5$/100 μl) were washed, incubated with Clear Back human Fc receptor blocking reagent for 5 min at 4°C and then stained with the following mAbs at 4°C for 30 min: FITC-conjugated anti-human CD14 (dilution 1:20; cat. no. 11-0149-42; clone 61D3; eBioscience; Thermo Fisher Scientific, Inc.); FITC-conjugated anti-CD8 (dilution 1:60; cat. no. 301006; clone RPA-T8), PE-conjugated anti-human CD19 (dilution 1:40; cat. no. 302208; clone HIB19), allophycocyanin (APC)-conjugated anti-human CD56 (dilution 1:20; cat. no. 318310; clone HCD56) and APC/cyanine 7 (Cy7)-conjugated anti-human CD4 (dilution 1:60; cat. no. 317418; clone OKT4; all from BioLegend, Inc.). Phenotypes were analyzed using an Attune NxT flow cytometer (Thermo Fisher Scientific, Inc.) and FlowJo analysis software (version 7.6.5; Tree Star, Inc.). Prior to using the analyzer, 4 μg/ml propidium iodide (Sigma-Aldrich; Merck KGaA) was added to the samples to exclude dead cells at 4°C for ~5 min.

Induction of WT1-reactive CD4+ and CD8+ T cells. Cryopreserved NAD cells were thawed, washed and incubated under 5% CO_2 at 37°C in a humidified incubator for 24 h in 24-well plates with RPMI-1640 medium (Sigma-Aldrich; Merck KGaA) supplemented with 1% minimum essential medium nonessential amino acids, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol (all from Gibco; Thermo Fisher Scientific, Inc.) and 10% heat-deactivated fetal calf serum (Cytiva) in the presence of IL-2 (20 U/ml; Shionogi & Co., Ltd.) and IL-7 (20 ng/ml; PeproTech, Inc.). The next day (day 1), WT1 HP_{34-51}-pulsed mDCs (mDC/WT1 HP_{34-51}; $1x10^5$) or WT1 KP_{37-45}-pulsed mDCs (mDC/WT1 KP_{37-45}; $1x10^5$) were cocultured with NAD cells ($1x10^6$) in RPMI-1640 medium containing 1% minimum essential medium nonessential amino acids, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol and 10%

heat-deactivated fetal calf serum in the presence of low doses of IL-2 (10 U/ml) and IL-7 (10 ng/ml) under 5% CO_2 at 37°C in a humidified incubator for 7 days. At day 8, the stimulated cells ($1x10^6$) were washed and cocultured again with freshly prepared mDC/WT1 HP_{34-51} ($1x10^5$) or mDC/WT1 KP_{37-45} ($1x10^5$) in the fresh culture medium containing IL-2 (10 U/ml) and IL-7 (10 ng/ml) for 7 days. To generate WT1-reactive T cells effectively, the stimulation was repeated in the same manner for a total of 4 times (day 1, 8, 15 and 22). In addition, as a control (no stimulation group), NAD cells ($1x10^6$) were maintained with IL-2 (10 U/ml) and IL-7 (10 ng/ml) in 7-day intervals for a total of 4 times under 5% CO_2 at 37°C in a humidified incubator.

Microscopic analysis of cell clusters. On day 4 of the final 7-day simulation interval (day 26), cell cluster formation was examined under a EVOS™ XL core imaging system (magnification, x4; cat. no. AMEX1000; Thermo Fisher Scientific, Inc.).

Detection of CD4+ or CD8+ T cells producing IFN-γ in response to WT1-KP_{37-45}. To assess the impact of mDC/WT1 HP_{34-51} on the activation of WT1-specific T cells, WT1-reactive T cells ($1x10^5$) induced by 4 total stimulations with mDC/WT1 HP_{34-51} or mDC/WT1 KP_{37-45} were restimulated once with WT1 HP_{34-51}-pulsed imDCs (imDC/WT1 HP_{34-51}), WT1 KP_{37-45}-pulsed imDCs (imDC/WT1 KP_{37-45}) or imDCs ($1x10^4$) alone in 96-well U-bottomed plates (Corning Inc.) under 5% CO_2 at 37°C in a humidified incubator for 6 h using BD GolgiStop (BD Biosciences). After stimulation, the cells were washed, incubated with Clear Back human Fc receptor blocking reagent for 5 min at 4°C and then stained with a PE/Cy5-conjugated anti-human CD8 mAb (dilution 1:20; cat. no. 15-0088-71; clone RPA-T8; eBioscience; Thermo Fisher Scientific, Inc.) and an APC/Cy7-conjugated anti-human CD4 mAb (dilution 1:60; cat. no. 317418; clone OKT4; BioLegend, Inc.). Thereafter, they

were washed, fixed at 4˚C for 20 min and then permeabilized using a BD Cytofix/Cytoperm Plus Fixation/Permeabilization kit with BD GolgiStop (BD Biosciences). The cells were then incubated with an APC-conjugated anti-human IFN-γ mAb (dilution 1:25; cat. no. 506510; clone B27; BioLegend, Inc.). Lymphocytes were gated on an forward scatter-side scatter (FSC-SSC) dot plot, and CD4$^+$ or CD8$^+$ T cells were regated on a CD4/IFN-γ or CD8/IFN-γ dot plot, respectively. The percentages of CD4$^+$IFN-γ$^+$ cells and CD8$^+$IFN-γ$^+$ cells among the CD4$^+$ or CD8$^+$ T cell population, respectively, were analyzed using the same equipment and software as were used to analyze DC/NAD phenotypes.

WT1-specific memory cells in CD4$^+$ or CD8$^+$ T cell populations induced by mDC/WT1 HP$_{34-51}$. To assess the memory cell subsets of activated WT1-reactive CD4$^+$ or CD8$^+$ T cells, NAD cells were first stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ for 4 times, followed by restimulation with imDC/WT1 KP$_{37-45}$ at a ratio of 10:1 under 5% CO$_2$ at 37˚C in a humidified incubator. NAD cells without any stimulation were maintained and used as a control. After stimulation, the cells were washed, incubated with Clear Back human Fc receptor blocking reagent as previously described and then stained with an FITC-conjugated anti-human exon 4 splice variant of the tyrosine phosphatase (CD45RA) mAb (dilution 1:40; cat. no. 304106; clone HI100; BioLegend, Inc.), a PE-conjugated anti-human chemokine receptor type 7 (CCR7) mAb (dilution 1:10; cat. no. FAB-197P; clone 150503; R&D Systems, Inc.), or a PE/Cy5-conjugated anti-human CD8 mAb and an APC/Cy7-conjugated anti-human CD4 mAb at 4˚C for 30 min. Lymphocytes were gated on an FSC-SSC dot plot, CD4$^+$ or CD8$^+$ T cells were regated, and CD45RA and CCR7 were then analyzed using the same equipment and software as were used to analyze DC/NAD phenotypes. Activated CD4$^+$ or CD8$^+$ T cells can be classified into 4 groups based on CD45RA and CCR7: CD45RA$^+$CCR7$^+$ naïve, CD45RA$^-$CCR7$^+$ central memory (CM), CD45RA$^-$CCR7$^-$ effector memory (EM) and CD45RA$^+$CCR7$^-$ terminally differentiated effector memory (EMRA) cells.

Statistical analysis. Data are presented as the mean ± SD. Comparisons of the difference in the percentage of cell surface markers between imDCs and mDCs were performed with a paired t-test or a Wilcoxon signed-rank test. P<0.05 was considered to indicate a statistically significant difference. Statistical analyses were performed using Microsoft Office Excel 2011 (Microsoft Corporation) with the add-in software Statcel 3 (OMS Publishing Inc.).

Results

Binding of WT1 peptides to MHC class I or MHC class II molecules. According to the NetMHC 4.0 server-prediction program, WT1 KP$_{37-45}$ within WT1 HP$_{34-51}$ exhibited high affinity for HLA-A*02:01 and A*02:07. Moreover, according to the NetMHCII-2.3 server-prediction program, WT1 HP$_{34-51}$ and WT1 KP$_{37-45}$ exhibited high affinity for MHC class II (data not shown).

Characterization of imDCs, mDCs or NAD cells. Frozen and stored PBMCs were used, and the yield of mDCs at the end of the

production process was 2.47±1.86% (n=3). As not enough cells were available for patients 4 and 9, the immunophenotype results of the imDCs and mDCs from the 12 cases are presented in Tables SI and SII. Both imDCs and mDCs generated from 12 of the analyzed cancer patients displayed a characteristic phenotype comprising MHC class I (HLA-ABC), MHC class II (HLA-DR), CD14, CD11c, CD80, CD86, CD40 and CD83 expression (Fig. S1, Tables SI and SII). In addition, the percentages of mDCs expressing CD80, CD86, CD40 and CD83 were significantly increased compared with imDCs (P<0.001, P=0.002, P=0.021 and P<0.001, respectively), indicating that mDCs were activated by exposure of imDCs to OK-432 (Tables SI and SII). In contrast, the NAD cell composition (n=5) included lymphocytes (CD8$^+$ cells, 27.14±8.44%; CD4$^+$ cells, 54.49±10.38%; CD19$^+$ cells, 0.78±0.42%; CD56$^+$ cells, 9.80±3.86%) and monocytes (CD14$^+$ cells, 2.24±1.20%; data not shown).

WT1-reactive T cells generated by mDC/WT1 HP$_{34-51}$ stimulation. To assess the stimulatory capacity of mDC/WT1 HP$_{34-51}$ for induction of HLA-A*02:01-restricted CD8$^+$ T cells, NAD cells from patient 4 (HLA-A*02:01/24:02; Table I) were first stimulated 4 times in 7-day intervals with mDC/WT1 HP$_{34-51}$. As a control, NAD cells were also first cultured with mDC/WT1 KP$_{37-45}$, or not stimulated but maintained with low doses of IL-2 and IL-7 4 times in 7-day intervals. The cells were then restimulated with imDC/WT1 HP$_{34-51}$, imDC/WT1 KP$_{37-45}$ or imDCs alone (Fig. 1A). At 4 days after the final stimulation with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ (Fig. 1A), cell clusters had formed (Fig. 1B). In contrast, there was no cluster formation by cells in the no stimulation group (Fig. 1B). These results indicated that both mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ exhibited the ability to stimulate these cells.

Then, it was evaluated as to whether mDC/WT1 HP$_{34-51}$ induced WT1-reactive T cells with the functional capacity to produce IFN-γ by monitoring the activity of CD4$^+$ and CD8$^+$ T cells in response to imDC/WT1 HP$_{34-51}$ (Fig. 2A). The percentages of CD4$^+$IFN-γ$^+$ T cells among total CD4$^+$ T cells were 0.58% [0.29/(0.29+49.4)] and 0.58% [0.28/(0.28+48.4)] after restimulation with imDC/WT1 HP$_{34-51}$ or imDCs alone, respectively (Fig. 2B). In contrast to CD4$^+$ T cells, the percentages of CD8$^+$IFN-γ$^+$ T cells among total CD8$^+$ T cells after restimulation with imDC/WT1 HP$_{34-51}$ or imDCs alone were 7.26% [3.10/(3.10+39.6)] and 0.05% [0.02/(0.02+43.9)], respectively (Fig. 2B). These results suggested that mDC/WT1 HP$_{34-51}$ possessed the ability to stimulate CD8$^+$ T cells that can produce IFN-γ.

Whether mDC/WT1 HP$_{34-51}$ had the capacity to induce IFN-γ-producing CD8$^+$ T cells similar to that of mDC/WT1 KP$_{37-45}$ was also evaluated (Fig. 3A). The percentages of CD4$^+$IFN-γ$^+$ T cells among total CD4$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ or left unstimulated, all of which were subsequently restimulated once with imDC/WT1 KP$_{37-45}$, were 0.68% [0.34/(0.34+49.3)], 1.00% [0.51/(0.51+50.3)], and 0.19% [0.08/(0.08+41.9)], respectively (Fig. 3B). Moreover, imDCs were used as a control for the second stimulator, and the percentages of CD4$^+$IFN-γ$^+$ T cells among total CD4$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ following restimulation with imDCs alone were 0.58% [0.28/(0.28+48.4); Fig. 2B] and

Figure 1. Stimulation of T cells with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$. (A) Schematic representation of methods to induce WT1-reactive CD4$^+$ and CD8$^+$ T cells. (B) At 4 days after 4 times stimulation with mDC/WT1 HP$_{34-51}$ (left) or mDC/WT1 KP$_{37-45}$ (middle) in 7-day intervals (day 26), but not incubation without stimulation (right), the formation of cell clusters (white arrows) was observed (magnification, x4). Representative images of two independent experiments are presented. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; mDC/WT1 KP$_{37-45}$, mDCs pulsed with WT1 KP$_{37-45}$; IL, interleukin.


Figure 2. Characterization of T cells stimulated with mDC/WT1 HP$_{34-51}$. (A) Nonadherent cells were first stimulated with mDC/WT1 HP$_{34-51}$. The activated T cells were restimulated with imDC/WT1 HP$_{34-51}$ or imDCs alone. (B) Dot plots of IFN-γ-producing CD4$^+$ (top) and CD8$^+$ T cells (bottom) derived from a patient with pancreatic ductal adenocarcinoma after stimulation with mDC/WT1 HP$_{34-51}$ and restimulation with imDC/WT1 HP$_{34-51}$ (left) or imDCs alone (right). Representative plots of two independent experiments are presented. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; imDC/WT1 HP$_{34-51}$, imDCs pulsed with WT1 HP$_{34-51}$; IFN-γ, interferon-γ.

0.68% [0.34/(0.34+49.6); Fig. S2], respectively. These results suggested that mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ exhibited a capacity to induce IFN-γ-producing CD4$^+$ T cells after restimulation with imDC/WT1 KP$_{37-45}$ when compared with no stimulation. In contrast to CD4$^+$ T cells, the percentages of CD8$^+$IFN-γ$^+$ T cells among total CD8$^+$ T cells stimulated 4 times with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ and restimulated once with imDC/WT1 KP$_{37-45}$ were 7.96% [3.39/(3.39+39.2)] and 5.13% [2.64/(2.64+48.8)], respectively (Fig. 3B). Furthermore, the percentages of CD8$^+$IFN-γ$^+$ T cells among total CD8$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ following restimulation with imDCs alone were 0.05% [0.02/(0.02+43.9); Fig. 2B] and 0.10% [0.05/(0.05+52.2); Fig. S2], respectively. In addition, 0.60% [0.30/(0.30+50.0)] of total CD8$^+$ T cells were CD8$^+$IFN-γ$^+$ following no stimulation during 29 days of culture and then one stimulation with imDC/WT1 KP$_{37-45}$ (Fig. 3B). Of note, CD8$^+$ T cells stimulated 4 times with mDC/WT1 HP$_{34-51}$ produced IFN-γ at higher levels than those stimulated 4 times with mDC/WT1 KP$_{37-45}$ after one restimulation with imDC/WT1 KP$_{37-45}$ (Fig. 3B). These results suggested that the combination treatment of mDC/WT1 HP$_{34-51}$ and imDC/WT1 KP$_{37-45}$ exhibited the capacity to induce IFN-γ-producing CD8$^+$ T cells more frequently than that of mDC/WT1 KP$_{37-45}$ and imDC/WT1 KP$_{37-45}$.

WT1-specific memory cells in activated CD4$^+$ or CD8$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$. As mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ stimulated WT1 KP$_{37-45}$-reactive CD4$^+$ T cells, patient 4 was selected for an analysis of the memory cell subsets of CD4$^+$ T cells (Fig. 4A). The percentages of EM cells among total CD4$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or left unstimulated were 78.3, 73.7 and 30.8%, respectively (Fig. 4B and C). The percentages of EMRA cells among total CD4$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ were 8.29 and 6.67%, respectively (Fig. 4B and C). These percentages were higher than those in the no stimulation group (3.54%). The results suggested that mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ induced EM and EMRA CD4+ T cells. Additionally, the percentage of naïve T cells among total CD4$^+$ T cells was decreased after stimulation with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ (Fig. 4B and C).

As mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ also stimulated WT1 KP$_{37-45}$-reactive CD8$^+$ T cells, patient 4 was also selected for an analysis of the memory cell subsets of CD8$^+$ T cells (Fig. 5A). In contrast to CD4$^+$ T cells, the percentages of EM cells among total CD8$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or left unstimulated after one restimulation with imDC/WT1 KP$_{37-45}$ were 51.3, 53.2 and 56.4%, respectively (Fig. 5B and C). The percentages of EMRA cells among total CD8$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or left unstimulated following one restimulation with imDC/WT1 KP$_{37-45}$ were

Figure 3. Comparison of the efficiencies of mDC/WT1 HP$_{34-51}$ and mDC/WT1 KP$_{37-45}$ in activating WT1-specific CD4$^+$ or CD8$^+$ T cells. (A) Nonadherent cells were first stimulated with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or IL-2/IL-7 alone. The activated T cells were restimulated with imDC/WT1 KP$_{37-45}$. (B) Dot plots of IFN-γ-producing CD4$^+$ (top) and CD8$^+$ T cells (bottom) derived from a patient with pancreatic ductal adenocarcinoma after stimulation with mDC/WT1 HP$_{34-51}$ (left), mDC/WT1 KP$_{37-45}$ (middle) or no stimulation (right) and restimulation with imDC/WT1 KP$_{37-45}$. Representative plots of two independent experiments are presented. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; mDC/WT1 KP$_{37-45}$, mDCs pulsed with WT1 KP$_{37-45}$; imDC/WT1 KP$_{37-45}$, imDCs pulsed with WT1 KP$_{37-45}$; IL, interleukin; IFN-γ, interferon-γ.

Figure 4. Memory cell subsets of CD4$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$. (A) Nonadherent cells were first stimulated 4 times with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or IL-2/IL-7 alone. The activated T cells were restimulated with imDC/WT1 KP$_{37-45}$. (B) Dot plots of the memory cell subsets in CD4$^+$ T cells derived from a patient with pancreatic ductal adenocarcinoma activated by mDC/WT1 HP$_{34-51}$ (left), mDC/WT1 KP$_{37-45}$ (middle) or no stimulation (right), followed by restimulation with imDC/WT1 KP$_{37-45}$. (C) Percentage of four subgroups (N, CM, EM or EMRA) of memory CD4$^+$ T cells activated by mDC/WT1 HP$_{34-51}$ (left), mDC/WT1 KP$_{37-45}$ (middle) or no stimulation (right), and restimulation with imDC/WT1 KP$_{37-45}$. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; mDC/WT1 KP$_{37-45}$, mDCs pulsed with WT1 KP$_{37-45}$; imDC/WT1 KP$_{37-45}$, imDCs pulsed with WT1 KP$_{37-45}$; IL, interleukin; N, naïve; CM, central memory; EM, effector memory; EMRA, terminally differentiated effector memory; CCR7, chemokine receptor 7; CD45RA, human exon 4 splice variant of the tyrosine phosphatase.

45.0, 42.4 and 37.6%, respectively (Fig. 5B and C). These results suggested that the frequencies of CD8$^+$ memory T cell subsets from a patient with PDA showed no notable differences between the mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ and no stimulation groups.

Induction of WT1-reactive CD4$^+$ or CD8$^+$ T cells derived from patients with different types of cancer by mDC/WT1 HP$_{34-51}$. The ability of mDC/WT1 HP$_{34-51}$ to induce WT1-reactive CD4$^+$ or CD8$^+$ T cells obtained from patients with different types of cancer and HLA-A2 alleles [02:01 (n=5), 02:06 (n=7), 02:07 (n=2)] was then subsequently assessed. For 10 (patients 1, 3, 5, 6, 7, 10, 11, 12, 13 and 14) of the 14 patients with cancer (71.4%), >1% of the total CD4$^+$ T cell population expressed IFN-γ after four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one restimulation with imDCs (Table II). Furthermore, for 10 (patients 1, 2, 4, 6, 7, 8, 9, 10, 13 and 14) of the 14 patients examined (71.4%), >10% of the total CD4$^+$ T cell population expressed IFN-γ after four rounds of stimulation with mDC/WT1 HP$_{34-51}$ and restimulation once with imDC/WT1 KP$_{37-45}$, which was higher compared with the percentage after restimulation once with imDCs alone (Table II). In contrast to the results for WT1-reactive CD4$^+$ T cells, >1% of the total CD8$^+$ T cell population from 10 (patients 1, 3, 5, 6, 7, 8, 10, 11, 12 and 13) of the 14 patients (71.4%)

examined produced IFN-γ after four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one stimulation with imDCs (Table III). For 6 (patients 2, 3, 4, 7, 9 and 14) of the 14 patients with cancer (42.9%), a >10% increase in the IFN-γ-producing CD8$^+$ T cell population among total CD8$^+$ T cells was detected after restimulation once with imDC/WT1 KP$_{37-45}$ compared with restimulation once with imDCs alone (Table III). WT1-reactive CD8$^+$ T cells from patient 14 with the HLA-A*02:07 allele exhibited greater IFN-γ production than the cells from the other patient with the HLA-A*02:07 allele. In summary, for 5 of the 12 patients with cancer (41.7%) with the HLA-A*02:01 or HLA-A*02:06 allele, WT1-reactive CD8$^+$ T cells stimulated with mDC/WT1 HP$_{34-51}$ exhibited enhanced levels of WT1 KP$_{37-45}$-induced IFN-γ production, with a >10% increase following one restimulation with imDC/WT1 KP$_{37-45}$ in this experimental setting. These results suggested that mDC/WT1 HP$_{34-51}$ generated from patients with different types of cancer may induce WT1-specific CD8$^+$ T cells at least in part in an HLA-A*02:01-, HLA-A*02:06- or HLA-A*02:07-restricted manner.

Figure 5. Memory cell subsets of CD8+ T cells stimulated with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$. (A) Nonadherent cells were first stimulated 4 times with mDC/WT1 HP$_{34-51}$, mDC/WT1 KP$_{37-45}$ or IL-2/IL-7 alone. The activated T cells were restimulated with imDC/WT1 KP$_{37-45}$. (B) Dot plots of the memory cell subsets in CD8+ T cells derived from a patient with pancreatic ductal adenocarcinoma activated by mDC/WT1 HP$_{34-51}$ (left), mDC/WT1 KP$_{37-45}$ (middle) or no stimulation (right), followed by restimulation with imDC/WT1 KP$_{37-45}$. (C) Percentage of four subgroups (N, CM, EM or EMRA) of memory CD8+ T cells activated by mDC/WT1 HP$_{34-51}$ (left), mDC/WT1 KP$_{37-45}$ (middle) or no stimulation (right), and restimulation with imDC/WT1 KP$_{37-45}$. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; mDC/WT1 KP$_{37-45}$, mDCs pulsed with WT1 KP$_{37-45}$; imDC/WT1 KP$_{37-45}$, imDCs pulsed with WT1 KP$_{37-45}$; IL, interleukin; N, naïve; CM, central memory; EM, effector memory; EMRA, terminally differentiated effector memory; CCR7, chemokine receptor 7; CD45RA, human exon 4 splice variant of the tyrosine phosphatase.

Discussion

The present study indicated that mDC/WT1 HP$_{34-51}$ exhibited the ability to induce not only WT1-reactive EM CD4+ Th1 cells but also CD8+ CTLs producing IFN-γ in an HLA-A*02:01- or HLA-A*02:06-restricted manner in an *in vitro* human model. The combination of mDC/WT1 HP$_{34-51}$ and imDC/WT1 KP$_{37-45}$ induced higher levels of IFN-γ-producing CD8+ T cells than stimulation with mDC/WT1 KP$_{37-45}$ and imDC/WT1 KP$_{37-45}$.

The impact of mDC/WT1 HP$_{34-51}$ on the activation of WT1-specific T cells was assessed by monitoring IFN-γ production following restimulation with imDC/WT1 HP$_{34-51}$ or imDC/WT1 KP$_{37-45}$. As restimulation with mDCs alone induced a degree of nonspecific IFN-γ production in the present study, WT1-loaded or unloaded imDCs were used as restimulators. CD4+ and CD8+ T cells were stimulated with mDC/WT1 HP$_{34-51}$ together at the same time, resulting in IFN-γ production after restimulation with imDC/WT1 HP$_{34-51}$ or imDC/WT1 KP$_{37-45}$, but not imDCs alone. Our previous phase I study with mDCs pulsed with a mixture

Table II. Percentage of IFN-γ-producing CD4+ T cells among total CD4+ T cells by stimulation with mDC/WT1 HP$_{34-51}$.

Case	HLA-A	Restimulation	
		imDC/WT1 KP$_{37-45}$	imDCs
1	02:01	4.97[a]	3.78
2	02:01	1.01[a]	0.64
3	02:01	6.93	6.99
4	02:01	0.68[a]	0.58
5	02:01	1.03	1.11
6	02:06	3.69[a]	2.34
7	02:06	10.26[a]	7.96
8	02:06	0.69[a]	0.58
9	02:06	0.85[a]	0.23
10	02:06	3.31[a]	2.81
11	02:06	2.5	2.43
12	02:06	3.17	3.72
13	02:07	1.79[a]	1.46
14	02:07	3.23[a]	1.48

[a]Indicates a >10% increase in the IFN-γ-producing CD4+ T cell frequency among total CD4+ T cells induced by four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one stimulation with imDC/WT1 KP$_{37-45}$, compared with imDCs alone. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; imDC/WT1 KP$_{37-45}$, imDCs pulsed with WT1 KP$_{37-45}$; IFN-γ, interferon-γ; HLA, human leukocyte antigen.

of three WT1 peptides, including WT1 HP$_{332-347}$ and WT1 KP, observed that simultaneous induction of WT1-specific CD4+ and CD8+ T cells was associated with improved long-term survival (4). The novel peptide WT1 HP$_{34-51}$ was subsequently developed to enhance WT1 peptide immunogenicity, and early clinical trials of a cocktail WT1 peptide vaccine containing the novel peptide WT1 HP$_{34-51}$ and WT1 KP have been conducted in patients with pediatric brain cancer or myelodysplastic syndromes (20,21). The results demonstrated WT1-specific CTL induction in clinical responders, suggesting that WT1 HP$_{34-51}$ has effective activity. Moreover, vaccination of a mouse model with both WT1 HP$_{34-51}$ and WT1 KP also induced strong infiltration of WT1-specific CD4+ Th1 cells and CD8+ CTLs into tumor microenvironments (17).

In general, simultaneous activation of WT1-specific CD4+ Th1 cells and CD8+ CTLs may be essential when treating patients with advanced-stage cancer. Notably, the novel WT1 HP$_{34-51}$ amino acid sequence includes WT1$_{37-45}$, which has binding affinity for HLA-A*02:01 molecules (18). Therefore, the novel peptide WT1 HP$_{34-51}$ may stimulate not only WT1-specific CD4+ T cells but also CD8+ T cells in a manner, at least in part, restricted by HLA-A*02:01 molecules. To evaluate this hypothesis, a patient with PDA possessing HLA-A*02:01/24:02 alleles was initially selected for further analysis. Notably, mDC/WT1 HP$_{34-51}$ activated not only

Table III. Percentage of IFN-γ-producing CD8$^+$ T cells among total CD8$^+$ T cells by stimulation with mDC/WT1 HP$_{34-51}$.

Case	HLA-A	Restimulation	
		imDC/WT1 KP$_{37-45}$	imDCs
1	02:01	3.11	3.87
2	02:01	1.84[a]	0.7
3	02:01	32.96[a]	11.07
4	02:01	7.96[a]	0.05
5	02:01	0.92	1.11
6	02:06	10.18	12.39
7	02:06	18.16[a]	12.61
8	02:06	0.72	1.22
9	02:06	0.62[a]	0.46
10	02:06	4.39	4.15
11	02:06	2.31	2.78
12	02:06	5.86	7.8
13	02:07	3.53	3.57
14	02:07	1.0[a]	0.8

[a]Indicates a >10% increase in the IFN-γ-producing CD8$^+$ T cell frequency among total CD8$^+$ T cells induced by four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one stimulation with imDC/WT1 KP$_{37-45}$, compared with imDCs alone. mDC, mature dendritic cell; imDC, immature dendritic cell; WT1, Wilms' tumor 1; HP$_{34-51}$, helper peptide; KP$_{37-45}$, killer peptide; mDC/WT1 HP$_{34-51}$, mDCs pulsed with WT1 HP$_{34-51}$; imDC/WT1 KP$_{37-45}$, imDCs pulsed with WT1 KP$_{37-45}$; IFN-γ, interferon-γ; HLA, human leukocyte antigen.

CD4$^+$ T cells but also CD8$^+$ T cells to produce IFN-γ after restimulation with imDC/WT1 KP$_{37-45}$, which according to the NetMHC 4.0 server-prediction program has a high affinity for HLA-A*02:01 but not for HLA-A*24:02. Thus, WT1-specific CD8$^+$ T cells from patient 4 induced by mDC/WT1 HP$_{34-51}$ may be HLA-A*02:01-restricted.

Stimulation of T cells by 4 incubations with mDC/WT1 HP$_{34-51}$, followed by one restimulation with imDC/WT1 HP$_{34-51}$ or imDC/WT1 KP$_{37-45}$ resulted in IFN-γ production by CD8$^+$ T cells. When imDCs are pulsed with WT1 HP$_{34-51}$, WT1 HP$_{34-51}$ may be taken up by imDCs, which can be activated by OK-432. Both imDCs and mDCs may be able to process WT1 HP$_{34-51}$ and load WT1 KP$_{37-45}$ onto HLA-A*02:01 molecules in the endoplasmic reticulum, resulting in their surface expression of WT1 KP$_{37-45}$/HLA-A*02:01 complexes for presentation to CD8$^+$ T cells. Endogenously processed WT1 in DCs has relatively good access to MHC class I and II molecules, resulting in the efficient induction of antitumor immunity (22). Thus, mDC/WT1 HP$_{34-51}$, imDC/WT1 HP$_{34-51}$ or imDC/WT1 KP$_{37-45}$ may also stimulate CD8$^+$ T cells through WT1 KP$_{37-45}$/HLA-A*02:01 complexes, resulting in the production of IFN-γ.

Indeed, a >10% increase in IFN-γ-producing cells among total CD8$^+$ T cells was detected in 3 of 5 patients with the HLA-A*02:01 allele and 2 of 7 patients with the HLA-A*02:06 allele when their NAD cells were stimulated

4 times with mDC/WT1 HP$_{34-51}$ followed by restimulation with imDC/WT1 KP$_{37-45}$ compared with restimulation with imDCs alone. Therefore, WT1 HP$_{34-51}$ may have the ability to induce WT1-specific CD8$^+$ CTLs in patients with cancer carrying the HLA-A*02:01 or HLA-A*02:06 allele. Nonetheless, 1 of 2 cancer patients with the HLA-A*02:07 allele exhibited IFN-γ production by CD8$^+$ T cells. According to the NetMHC 4.0 server-prediction program, WT1 KP$_{37-45}$ within WT1 HP$_{34-51}$ has a relatively high affinity for HLA-A*02:07. However, as HLA-A*02:07$^+$ patients are not a major population according to the national marrow donor program (23), only two patients with HLA-A*02:07 were enrolled in the present study. Accordingly, further studies are required to assess whether mDC/WT1 HP$_{34-51}$ consistently induces HLA-A*02:07-restricted WT1-specific CD8$^+$ T cells in patients with cancer.

Among the total CD8$^+$ T cell populations from patients with cancer, WT1-specific IFN-γ-producing CD8$^+$ T cells were more frequently induced by four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one stimulation with imDC/WT1 KP$_{37-45}$ compared with four rounds of stimulation with mDC/WT1 KP$_{37-45}$ followed by one stimulation with imDC/WT1 KP$_{37-45}$. Previous reports indicate that CD4$^+$ and CD8$^+$ T cell stimulation occurs when peptide vaccination with combined WT1 HP and WT1 KP is performed; however, vaccination with WT1 HP alone does not strongly activate T cells (4,17). It has also been reported that activation of CD4$^+$ T cells is essential for CD8$^+$ CTL induction, potentiating CD8$^+$ CTL proliferation and maintaining effector functions in the tumor microenvironment (5,24). Therefore, effective cancer vaccines must include a mechanism to activate CD4$^+$ T cells. Simultaneous activation of CD4$^+$ and CD8$^+$ T cells by DCs pulsed with both WT1 HP$_{34-51}$ and WT1 KP$_{37-45}$ may improve the efficient induction of WT1-specific CD8$^+$ T cells that produce IFN-γ. In fact, for 10 of the 14 patients in the present study, a >10% increase in the IFN-γ-producing CD4$^+$ T cell population among total CD4$^+$ T cells was induced by four rounds of stimulation with mDC/WT1 HP$_{34-51}$ followed by one stimulation with imDC/WT1 KP$_{37-45}$. According to the NetMHCII-2.3 server-prediction program, WT1 KP$_{37-45}$, which is a part of WT1 HP$_{34-51}$, has a relatively high affinity for MHC class II. Thus, WT1 KP$_{37-45}$ may also be present in MHC class II with imDC/WT1 KP$_{37-45}$, resulting in stimulation of CD4$^+$ T cells producing IFN-γ. As one of the major subtypes of HLA-A molecule is HLA-A*24:02 (23), mDCs may be pulsed with a cocktail of WT1 HP$_{34-51}$ and WT1 KP$_{235-243}$ for HLA-A*24:02 (4) to maximize the induction and maintenance of CD4$^+$ Th1 cells and CD8$^+$ CTLs, at least in part, in an HLA-A*02:01-, HLA-A*02:06- or HLA-A*24:02-restricted manner for application in a wider cohort of patients with cancer.

WT1-reactive CD4$^+$ T cells from patient 4 induced by mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$ stimulation were almost all EM T cells, whereas those maintained with low doses of IL-2 and IL-7 were not. In contrast, cancer patient CD4$^+$ T cells in the no stimulation group were almost all naïve. Naïve T cells differentiated into EM T cells via the effector T cell route (25) by undergoing several rounds of stimulation with mDC/WT1 HP$_{34-51}$ or mDC/WT1 KP$_{37-45}$. It has been reported that peptide-specific memory T cell

frequencies are increased in vaccine responders with a positive delayed-type hypersensitivity (DTH) test (4,26-28). Our previous study also demonstrated that in super-responders with WT1-specific DTH induced by vaccination with mDCs pulsed with WT1 HP and WT1 KP, continuous elicitation of WT1-specific long-lived EM and CM T cells occurred and could be boosted; these long-lived WT1-specific EM T cells patrol and recognize tumor cells and are therefore associated with a clinical benefit (4). Although EM CD4$^+$ T cells were induced by mDC/WT1 HP$_{34-51}$ stimulation, compared with EM CD4+ T cells, the EM CD8$^+$ T cell frequency was not strongly increased. As some WT1 overexpression occurs in various types of solid tumor, WT1-specific CD8$^+$ T cells are spontaneously induced (11-13), suggesting that some memory CD8$^+$ T cells may be detected without any stimulation *in vitro*. As memory CD4$^+$ T cells particularly support the priming and maintaining of antigen-specific CD8$^+$ T cells (29,30), the increase in memory CD4$^+$ T cell frequency induced by mDC/WT1 HP$_{34-51}$ stimulation may support an increase in WT1-reactive CD8$^+$ T cell frequency. In summary, T cells stimulated with mDC/WT1 HP$_{34-51}$ may have the capacity to elicit WT1-specific EM CD4$^+$ T cells and CD8$^+$ CTLs, which was at least in part restricted by HLA-A*02:01 or HLA-A*02:06, both of which produce IFN-γ. However, the memory cell subsets were only analyzed in a single case, a patient with PDA, as a sufficient number of cells was not available. The induction and maintenance of the durable memory type of CD4$^+$ Th1 cells by mDC/WT1 HP$_{34-51}$ may produce promising clinical activity to prolong overall survival in advanced-stage cancer patients.

As a sufficient number of PBMCs and autologous tumor cells were not available, the killing activity of WT1-ractive T cells induced by mDC/WT1 HP$_{34-51}$ could not be assessed in this preclinical study. A phase I clinical trial involving patients with advanced pancreatic cancer who express HLA-A*02:01, HLA-A*02:06 or HLA-A*24:02 is being performed using mDCs pulsed with a novel peptide cocktail containing WT1 HP$_{34-51}$ and HLA-A*24:02-restricted WT1 KP$_{235-243}$ combined with standard chemotherapy; the results of this clinical trial will be available soon. Additionally, future studies should optimize cancer vaccines incorporating mDCs loaded with an immunogenic novel WT1 peptide cocktail in combination with an immune checkpoint-blocking antibody.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

SKa and TB performed the experiments. SKa, TB and SKo analyzed the data. MS and JT collected patient samples, and analyzed and interpreted data. SKa, SS, TO, HS and SKo conceived and designed the experimental study. SKa and SKo wrote the manuscript. All authors discussed, read and approved the final manuscript.

Ethics approval and consent to participate

The present study was reviewed and approved by the Ethics Committee of the Jikei Institutional Review Board, Jikei University School of Medicine and the Clinical Study Committee of Jikei University Kashiwa Hospital [approval no. 29-093 (8679)].

Patient consent for publication

Not applicable.

Competing interests

HS is an inventor on the patents for the WT1 peptides used in the present study (PCT/JP02/02794 and PCT/2010/057149), which are held by the International Institute of Cancer Immunotherapy.

References

1. Steinman RM and Banchereau J: Taking dendritic cells into medicine. Nature 449: 419-426, 2007.
2. Baldin AV, Savvateeva LV, Bazhin AV and Zamyatnin AA Jr: Dendritic cells in anticancer vaccination: Rationale for ex vivo loading or in vivo targeting. Cancers (Basel) 12: 590, 2020.
3. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10: 909-915, 2004.
4. Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al: Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res 20: 4228-4239, 2014.
5. Melseen M and Slingluff CL Jr: Vaccines targeting helper T cells for cancer immunotherapy. Curr Opin Immunol 47: 85-92, 2017.
6. Taniuchi I: CD4 helper and CD8 cytotoxic T cell differentiation. Annu Rev Immunol 36: 579-601, 2018.
7. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Nakajima H, Elisseeva OA, Harada Y, Li Z, Tatsumi N, Kamino E, et al: A WT1 protein-derived, naturally processed 16-mer peptide, WT1(332), is a promiscuous helper peptide for induction of WT1-specificTh1-type CD4(+) T cells. Microbiol Immunol 52: 591-600, 2008.
8. Koski GK, Koldovsky U, Xu S, Mick R, Sharma A, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, et al: A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 35: 54-65, 2012.
9. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, Weinstein S, Nisenbaum H, Levine BL, Fox K, et al: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118: 4354-4362, 2012.
10. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, Schreibelt G, Mus R, De Wilt JH, Haanen JB, et al: Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 73: 19-29, 2013.

11. Chever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, *et al*: The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.

12. Huff V: Wilms' tumours: About tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 11: 111-121, 2011.

13. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, *et al*: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccinean the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004.

14. Takahara A, Koido S, Ito M, Nagasaki E, Sagawa Y, Iwamoto T, Komita H, Ochi T, Fujiwara H, Yasukawa M, *et al*: Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Cancer Immunol Immunother 60: 1289-1297, 2011.

15. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, *et al*: WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 59: 1467-1479, 2010.

16. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E and Sugiyama H: Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 19: 1318-1323, 2005.

17. Nakata J, Nakajima H, Hayashibara H, Imafuku K, Morimoto S, Fujiki F, Motooka D, Okuzaki D, Hasegawa K, Hosen N, *et al*: Extremely strong infiltration of WT1-specific CTLs into mouse tumor by the combination vaccine with WT1-specific CTL and helper peptides. Oncotarget 9: 36029-36038, 2018.

18. Schmied S, Gostick E, Price DA, Abken H, Assenmacher M and Richter A: Analysis of the functional WT1-specific T cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation. Immunology 145: 558-569, 2015.

19. Hori S, Heike Y, Takei M, Maruyama M, Inoue Y, Lee JJ, Kim HJ, Harada Y, Kawai H, Shimosaka A, *et al*: Freeze-thawing procedures have no influence on the phenotypic and functional development of dendritic cells generated from peripheral blood CD14+ monocytes. J Immunother 27: 27-35, 2004.

20. Goto M, Nakamura M, Suginobe N, Takasu H, Takanashi Y, Ban H and Li C: DSP-7888, a novel cocktail design of WT1 peptide vaccine, and its combinational immunotherapy with immune checkpoint-blocking antibody against PD-1. Blood 128: 4715-4715, 2016.

21. Miyakoshi S, Usuki K, Matsumura I, Ueda Y, Iwasaki H, Miyamoto T, Origuchi M, Tagashira S, Naoi I, Naoe T, *et al*: Preliminary results from a phase 1/2 study of DSP-7888, a novel WT1 peptide-based vaccine in patients with myelodysplastic syndrome (MDS). Blood 128: 4335-4335, 2016.

22. Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, *et al*: Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation. Eur J Immunol 43: 2554-2565, 2013.

23. Maiers M, Graget L and Klitz W: High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 68: 779-788, 2007.

24. Mintern JD, Davey GM, Belz GT, Carbone FR and Heath WR: Cutting edge: Precursor frequency affects the helper dependence of cytotoxic T cells. J Immunol 168: 977-980, 2002.

25. Lanzavecchia A and Sallusto F: Dynamics of T lymphocyte responses: Intermediates, effectors, and memory cells. Science 290: 92-97, 2000.

26. Wedén S, Klemp M, Gladhaug IP, Møller M, Eriksen JA, Gaudernack G and Buanes T: Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras. Int J Cancer 128: 1120-1128, 2011.

27. Nishida S, Koido S, Takeda Y, Homma S, Komita H, Takahara A, Morita S, Ito T, Morimoto S, Hara K, *et al*: Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. J Immunother 37: 105-114, 2014.

28. Lesterhuis WJ, de Vries IJ, Schuurhuis DH, Boullart AC, Jacobs JF, de Boer AJ, Scharenborg NM, Brouwer HM, van de Rakt MW, Figdor CG, *et al*: Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: Antigen-specific T cell responses in DTH skin tests. Ann Oncol 17: 974-980, 2006.

29. MacLeod MK, Clambey ET, Kappler JW and Marrack P: CD4 memory T cells: What are they and what can they do? Semin Immunol 21: 53-61, 2009.

30. Krawczyk CM, Shen H and Pearce EJ: Memory CD4 T cells enhance primary CD8 T-cell responses. Infect Immun 75: 3556-3560, 2007.